Natus Medical announced it acquired the remaining minority shares in Holberg EEG and now owns 100% of the company.
Middleton, Wisconsin–based Natus touts Holberg as the developer of the world’s first AI model capable of automatic and comprehensive clinical EEG interpretation with accuracy “on par with leading medical experts.” The acquisition brings the Holberg EEG technology into the neurodiagnostics portfolio at Natus. It creates new opportunities to advance brain health through smarter, more accessible solutions.
Related: RDS raises €14m to bolster market penetration of patient monitoring wearable
Holberg’s AI model delivers efficiency and diagnostic confidence in interpreting complex EEG data. The company’s flagship autoScore innovation came to the U.S. market in 2024. Using a deep-learning model trained on more than 30,000 EEG recordings, it alleviates the demands on clinical resources.
By integrating it with trusted EEG and neurodiagnostic solutions at Natus, providers can benefit from streamlined workflows, enhanced accuracy and improved patient outcomes. Natus plans to offer it exclusively on its NeuroWorks software for routine EEG, long-term monitoring and ambulatory EEG studies. It has FDA 510(k) clearance and CE mark.
Natus already offers a series of solutions to screen, diagnose, and treat disorders affecting the brain and neural pathways. That includes BrainWatch, its point-of-care EEG solution driven by AI, which it launched in May.
“Bringing Holberg EEG into the Natus family is an exciting and strategic milestone for our company and the field of neurodiagnostics,” said Chris Landon, CEO of Natus. “This acquisition allows us to accelerate the adoption of cutting-edge AI technology that empowers healthcare providers and technologists with faster, more accurate EEG interpretation – improving patient outcomes worldwide. We are proud to unite our deep heritage in neuro care with Holberg’s groundbreaking innovation, creating a powerful force for advancing brain health for decades.”
